Steering Group Members

David Back is Professor (Emeritus) of Pharmacology at the University of Liverpool and has worked in the area of pharmacokinetics and drug-drug interactions for more than 30 years. He established the Liverpool HIV Pharmacology Group (LHPG) in 1987 and subsequently the Liverpool group has been at the forefront of pharmacological research of anti-HIV drugs. Currently there are numerous ongoing pharmacokinetic, pharmacogenetic and molecular- based studies involving local, national and international collaborations.

David has authored ~450 publications. He is a former Editor of the British Journal of Clinical Pharmacology and is on the Editorial Board of numerous journals. In 2007 he was awarded the Lilly Prize from the British Pharmacological Society for outstanding contribution to Clinical Pharmacology and in 2015 a Lifetime achievement award from EACS.

Saye Khoo is a Professor of Clinical Pharmacology at the University of Liverpool and Honorary Consultant Physician in Infectious Diseases.

Professor Khoo is actively involved in HIV service development locally and nationally. Research interests centre on the pharmacology of HIV treatment failure. This includes the role of therapeutic drug monitoring, population pharmacokinetic modelling, investigation of drug interactions, molecular characterisation of drug metabolism and disposition pathways and the role of host genetic variability in influencing drug exposure and response. There is also a focus on HIV therapy in resource-poor settings, and the pharmacology of anti-tuberculous therapy.

He currently serves on the British HIV Association Treatment Guidelines Committee, the PENTA Pharmacology Steering Group, and is on the editorial board of several journals.

Fiona Marra is Lead Clinician for paediatric infectious disease for Scotland, and Senior Pharmacist for adult HCV/HIV in Gartnavel hospital, Glasgow. She has a Masters Degree in Pharmacy, MSc in advanced pharmacy and clinical diplomas in International development and Travel Medicine. She is also studying for a PhD in Clinical Pharmacology.

Fiona gained her interest in Infectious Disease when living in West Africa. Fiona sits on the board of the Scottish Malaria Group, Hepatitis C Lead Clinicians, British HIV Association (BHIVA) Hepatitis Group and is part of the Editorial board of Scottish paediatric Infection and Immunology network (SPAIIN). She is an author of the EASL Recommendations for HCV 2018 and 2020 and lectures globally on HIV and HCV drug interactions.

David Burger (Oct. 20, 1964) received his Pharmacy Degree at the Utrecht University in 1990. He completed his PhD thesis, titled “Bio-analysis and clinical pharmacokinetics of antiretroviral agents in HIV-infected individuals” at the Slotervaart Hospital, Amsterdam, in 1994. After this, he moved to the Radboud University Medical Centre, Nijmegen, for his hospital pharmacist training. 

Since 1997 he has been leading a research group focussing on clinical pharmacology of antimicrobial agents with emphasis on HIV, TB, fungal infections, and HCV. He is a member of the Editorial Board of the www.hiv-druginteractions.org and www.hep-druginteractions.org websites on behalf of the European AIDS Clinical Society.  More recently, a research line on clinical pharmacology of cancer treatment was initiated within the Department of Pharmacy; as a result David is now on the Editorial Board of http://www.cancer-druginteractions.org.

He is a Section Editor of the British Journal of Clinical Pharmacology and a member of the editorial boards of TDM, JAIDS, JAC, Antiviral Therapy.

Since April 2011 he has been appointed as a Professor of Clinical Pharmacy at the Radboud University Nijmegen. He is (co-) author of more than 400 publications in this field and has supervised 25 completed PhD theses. The topics of his interest are drug-drug interactions, pediatric pharmacology, therapeutic drug monitoring, and operational research in resource-limited countries.

Professor Dieterich is currently Professor of Medicine in the Division of Liver Diseases and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York, NY. He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases. He graduated from Yale University and received his Doctorate of Medicine from New York University of Medicine. Professor Dieterich has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health and is an investigator for many ongoing clinical trials evaluating the safety and efficacy of new antiviral treatments for chronic hepatitis B & C.

Jennifer Kiser is an Assistant Professor at the University of Colorado Denver. She earned her PharmD from the University of North Carolina at Chapel Hill and completed a residency at the University of California San Diego Medical Center and fellowship at the University of Colorado Denver. Her research interests are determining concentration-effect relationships and investigating drug-drug interactions for antiviral drugs. Dr. Kiser’s laboratory is a leader in the development of state of the art analytical methods to quantitate antiviral drug concentrations in various biologic matrices. She is involved in several local, national, and international antiviral clinical pharmacology studies in persons with viral hepatitis and HIV.